Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
NCT06408935 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to evaluate the efficacy of guselkumab in healing of all layers of the digestive tract (transmural healing) with the help of a score called Magnetic Resonance Index of Activity (MaRIA) based on a scan at Week 48.
Conditions Studied
Interventions
- DRUG Guselkumab
Study Locations (20)
Other
- The Queen Elizabeth Hospital — Adelaide
- Concord Repatriation General Hospital — Concord
- Northern Hospital — Melbourne
- Fiona Stanley Hospital — Murdoch
- Mater Hospital Brisbane — South Brisbane
- AZ Maria Middelares — Ghent
- CHU de Liege — Liège
- Vitaz — Sint-Niklaas
- Cliged — Macaé
- Instituto Mederi de Pesquisa e Saude — Passo Fundo
- NPCRS Nucleo de Pesquisa Clinica do Rio Grande do Sul — Porto Alegre
- INTEGRAL Pesquisa e Ensino — Votuporanga
- Nemocnice Ceske Budejovice a s — České Budějovice
California
- Center for Colitis and Crohns Disease University of California — San Francisco
Illinois
- The University of Chicago Medical Center (UCMC) — Chicago
Missouri
- Washington University School Of Medicine — St Louis
South Carolina
- Medical University of South Carolina — Charleston
Alberta
- Foothills Hospital — Calgary
Ontario
- Western University & London Health Sciences Centre — London
Quebec
- Hopital du Sacre-Coeur de Montreal — Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2024-04-17 |
| Est. Completion | 2028-03-06 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06408935
The ClinicalTrials.gov registry entry for NCT06408935 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen-Cilag, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 1 intervention — of which Guselkumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06408935 reports 20 study locations spanning 8 distinct geographic areas — top geographies include Other, California, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06408935 about?
NCT06408935 is a clinical study titled "Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients". The purpose of this study is to evaluate the efficacy of guselkumab in healing of all layers of the digestive tract (transmural healing) with the help of a score called Magnetic Resonance Index of Activity (MaRIA) based on a scan at Week 48.
What is the current status of trial NCT06408935?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 112 participants. The study started on 2024-04-17. Estimated completion is 2028-03-06.
What conditions does trial NCT06408935 study?
This clinical trial studies the following conditions: Crohn's Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06408935?
The interventions under investigation include: Guselkumab (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06408935?
This trial is sponsored by Janssen-Cilag, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06408935 being conducted?
This trial has 20 study locations across California, Illinois, Missouri, South Carolina, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.